Ardent Health Partners Inc ARDT Stock Analysis
- NYSE
- Stock
- Market open · no trades yet today
$15.90 up $2.91, 22.40% at close Nov 5
Last close · Previous close $12.99
- Market cap
- $2.28BAt the Nov 5 close
- P/E ratio
- 28.91On last 12 months’ EPS
- Diluted EPS
- $0.55Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$15.90up $2.91, 22.40%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$12.99Nov 4
- Volume2.47MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume602.31KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $7.71 to $16.23; now $15.90
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ARDT beat the S&P 500 in 3 of 4 periods.
| Period | ARDT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ARDT: up 50.7% S&P 500: down 5.4% | ARDT beat the S&P 500 by 56.1 percentage points Beat |
| 3M | ARDT: up 42.5% S&P 500: down 4.5% | ARDT beat the S&P 500 by 47.0 percentage points Beat |
| YTD | ARDT: up 80.1% S&P 500: up 8.3% | ARDT beat the S&P 500 by 71.8 percentage points Beat |
| 1Y | ARDT: up 8.4% S&P 500: up 9.3% | ARDT trailed the S&P 500 by 0.9 percentage points Trailed |
$10,000 invested in ARDT a year ago (Nov 5, 2025) would be worth about $10,838 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $10,934.
ARDT beat the S&P 500 in all 4 periods.
| Period | ARDT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ARDT: up 50.7% S&P 500: down 5.4% | ARDT beat the S&P 500 by 56.1 percentage points Beat |
| 3M | ARDT: up 42.5% S&P 500: down 4.8% | ARDT beat the S&P 500 by 47.3 percentage points Beat |
| YTD | ARDT: up 80.1% S&P 500: up 7.5% | ARDT beat the S&P 500 by 72.6 percentage points Beat |
| 1Y | ARDT: up 8.4% S&P 500: up 8.2% | ARDT beat the S&P 500 by 0.2 percentage points Beat |
$10,000 invested in ARDT a year ago (Nov 5, 2025) would be worth about $10,838 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,818.
All-time high
$20.19
Closing high on . Now 21.2% below that record.
Split-adjusted daily closes since Jul 18, 2024.
Stock splits
ARDT hasn’t split since its price history begins in 2024.
Valuation
The Nov 5 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
28.9×The Nov 5 close ÷ diluted EPS over the last 12 months ($0.55)
The range covers daily P/E ratios from Jul 18, 2024 to Nov 5, 2026, each based on the previous 12 months of earnings.
ARDT trades at 28.9× its earnings over the last 12 months, above its 5-year median of 10.1×. In plain terms, buyers are paying about $29 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 0.4×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 1.7×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 11.5×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 13.37%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $3.82BAt the Nov 5 close
What it would cost to buy the whole business: the market cap at the Nov 5 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own ARDT DCF in Excel. Value Ardent Health Partners with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $6.41Bup 3.3%
- Net income
- $78.23Mdown 69.3%
- Diluted EPS
- $0.55down 70.1%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $1.45B | $26.32M | $0.19 |
| Q4 FY24 (Dec 31, 2024) | $1.61B | $114.20M | $0.84 |
| Q1 FY25 (Mar 31, 2025) | $1.50B | $41.38M | $0.29 |
| Q2 FY25 (Jun 30, 2025) | $1.65B | $72.95M | $0.52 |
| Q3 FY25 (Sep 30, 2025) | $1.58B | −$23.48M | −$0.17 |
| Q4 FY25 (Dec 31, 2025) | $1.61B | $44.96M | $0.32 |
| Q1 FY26 (Mar 31, 2026) | $1.60B | $39.85M | $0.28 |
| Q2 FY26 (Jun 30, 2026) | $1.62B | $16.90M | $0.12 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $4.87B | $154.26M | Not reported |
| FY22 (Dec 31, 2022) | $5.13B | $188.91M | $1.50 |
| FY23 (Dec 31, 2023) | $5.41B | $53.90M | $0.43 |
| FY24 (Dec 31, 2024) | $5.97B | $210.34M | $1.58 |
| FY25 (Dec 31, 2025) | $6.32B | $135.81M | $0.96 |
Margins
- Gross 17.4%
- Operating 4.0%
- Net 1.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $304.76MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$514.32MLast 12 months
- Capital spending$209.57MLast 12 months
- 4.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $13.03MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$13.03MLast 12 months
4% of free cash flow
Balance sheet
- $724.48MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$2.27BAs of Jun 30, 2026
- Net debt$1.54BAs of Jun 30, 2026
- 2.10As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 1.68As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 6.0%Last 12 months
Over the last 12 months, Ardent Health Partners’s net income was 6.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 1.5%Last 12 months
Over the last 12 months, Ardent Health Partners’s net income was 1.5% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Ardent Health Partners Inc
Ardent Health Partners Inc
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Headquarters
- Tennessee, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
ARDT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ARDT stock FAQ
What is ARDT stock’s price today?
Ardent Health Partners (ARDT) traded at $15.90 at the close on , up $2.91 (22.40%) from the previous close of $12.99. Over the past 52 weeks it has traded between $7.71 and $16.23.
What is Ardent Health Partners’s market cap?
Ardent Health Partners’s market capitalization is about $2.3 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $15.90 (how market cap works). Ardent Health Partners reported 143.35M shares outstanding at the end of its latest quarter ().
What is ARDT’s P/E ratio?
ARDT trades at 28.9 times its diluted earnings over the four quarters to ($0.55 per share), at the close. Over the past five years its P/E has ranged from 5.7 to 31.3, with a median of 10.1. (How the P/E ratio works.)
How much revenue does Ardent Health Partners make?
Ardent Health Partners reported $6.4 billion of revenue over the four quarters to , up 3.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $1.6 billion, down 1.4% from a year earlier.
Is Ardent Health Partners profitable?
Yes. Ardent Health Partners earned $78.2 million of net income over the four quarters to , a net margin of 1.2%, and its operating margin was 4.0% (what margins tell you).
What are ARDT’s earnings per share?
ARDT’s diluted earnings per share were $0.55 over the four quarters to , compared with $1.84 in the twelve months before. The latest quarter (Q2 FY26) brought $0.12 per share, against $0.52 a year earlier (how EPS works).
Does ARDT pay a dividend?
Ardent Health Partners hasn’t paid a dividend in the last twelve months.
What is ARDT’s 52-week high and low?
Over the past 52 weeks ARDT has traded as low as $7.71 and as high as $16.23. At $15.90 at the close on , it is 2.0% below that high and 106.2% above the low.
What is ARDT’s all-time high?
ARDT’s highest closing price was $20.19 on , adjusted for stock splits. At $15.90 at the close on , it is 21.2% below that record.
Has ARDT stock ever split?
No. ARDT hasn’t split since its price history begins in 2024.
How has ARDT stock performed?
Including dividends and measured to the close on , ARDT has returned +80.1% so far this year and +8.4% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.3% and +9.3%. Past performance doesn’t predict future returns.
What sector and industry is Ardent Health Partners in?
Ardent Health Partners is in the Healthcare sector and the Medical Care Facilities industry, and is headquartered in Tennessee, USA.
What exchange does ARDT trade on?
Ardent Health Partners trades on the NYSE under the ticker symbol ARDT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.